Off-target activity of NBOMes and NBOMe analogs at the µ opioid receptor

• Published in: Archives of toxicology Vol. 97; no. 5; pp. 1367 - 1384
• Main Authors: Deventer, Marie H., Persson, Mattias, Laus, Antonio, Pottie, Eline, Cannaert, Annelies, Tocco, Graziella, Gréen, Henrik, Stove, Christophe P.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.05.2023; Springer Nature B.V
• Subjects: Analgesics, Opioid - pharmacology; Analogs; Assaying; Biocompatibility; Biomedical and Life Sciences; Biomedicine; Calcium ions; Environmental Health; Hallucinogens - chemistry; Isomers; Molecular docking; Molecular Docking Simulation; Molecular Toxicology; Naloxone; Narcotics; Occupational Medicine/Industrial Medicine; Opioid receptors; Pharmacology/Toxicology; Phenethylamine; Psychedelic drugs; Receptors; Serotonin; Serotonin S2 receptors; Toxicity; µ opioid receptor; NBOMe; Bioassay; Off-target; Psychedelics; Molecular docking; mu opioid receptor
• ISSN: 0340-5761; 1432-0738; 1432-0738
• DOI: 10.1007/s00204-023-03465-9

New psychoactive substances (NPS) are introduced on the illicit drug market at a rapid pace. Their molecular targets are often inadequately elucidated, which contributes to the delayed characterization of their pharmacological effects. Inspired by earlier findings, this study set out to investigate the µ opioid receptor (MOR) activation potential of a large set of psychedelics, substances which typically activate the serotonin (5-HT 2A ) receptor as their target receptor. We observed that some substances carrying the N -benzyl phenethylamine (NBOMe) structure activated MOR, as confirmed by both the NanoBiT® βarr2 recruitment assay and the G protein-based AequoScreen® Ca 2+ release assay. The use of two orthogonal systems proved beneficial as some aspecific, receptor independent effects were found for various analogs when using the Ca 2+ release assay. The specific ‘off-target’ effects at MOR could be blocked by the opioid antagonist naloxone, suggesting that these NBOMes occupy the same common opioid binding pocket as conventional opioids. This was corroborated by molecular docking, which revealed the plausibility of multiple interactions of 25I-NBOMe with MOR, similar to those observed for opioids. Additionally, structure–activity relationship findings seen in vitro were rationalized in silico for two 25I-NBOMe isomers. Overall, as MOR activity of these psychedelics was only noticed at high concentrations, we consider it unlikely that for the tested compounds there will be a relevant opioid toxicity in vivo at physiologically relevant concentrations. However, small modifications to the original NBOMe structure may result in a panel of more efficacious and potent MOR agonists, potentially exhibiting a dual MOR/5-HT 2A activation potential.